Neurocrine Biosciences Reports Third Quarter 20... (cessed via the webcast through the Compa...)

Neurocrine Biosciences Reports Third Quarter 2009 Results

Date:10/28/2009

cessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 1-800-723-2156 (US) or 402-220-2660 (International) using the passcode 7NEURO. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program, R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; and risks associated with the Company's dependence on corporate c
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain

Post Your Comments:

(Date:5/24/2013)... BEIJING , May 24, 2013 China ... "Company"), a leading fully integrated plasma-based biopharmaceutical company in ... Company has recently learned from a public announcement issued ... a public company listed on Shenzhen Stock Exchange, that ... Chan ("Ms. Chan"), one of the shareholders ...

(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer"). On 20 May ...

(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...

[0] China Biologic Comments on the Proposed Shanghai RAAS Transaction [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany

... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) ... quarter and full year 2010 on Wednesday, January 26, 2011 ... president and chief executive officer, will lead the call. On ... the fourth quarter and year ended December 31, 2010. ...

... Applied Precision is pleased to announce that ... Dougherty, senior scientist, have been chosen to present ... BiOS SPIE Photonics West. Three-dimensional ... that doubles the lateral and axial resolution, providing ...

Cached Medicine Technology:Amylin Pharmaceuticals to Webcast Year-End Financial Results 2 Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco 2

Amylin Pharmaceuticals to Webcast Year-End Financial Results Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco

(Date:5/25/2013)... May 25, 2013 This week idcloak Technologies ... to Facebook in countries where the site is blocked. ... user faces none of the site compatibility problems associated with ... Technologies, explains how a user may apply IP Port proxies ... the benefits of doing so are. , “When a user ...

(Date:5/25/2013)... NYC,NY (PRWEB) May 25, 2013 Dr. ... only non-invasive procedure FDA-approved to lift skin on the neck, ... available at her practice, Medical Aesthetics. , Ultherapy is a ... body’s own natural healing process to lift the skin over ... the first time, to see and then treat the deepest ...

(Date:5/25/2013)... 25, 2013 Actos lawsuit ... U.S. District Court, Western District of Louisiana, continue to ... a Case Management Order issued on May 21st, the ... contested motions in the Actos bladder cancer litigation, as ... Actos Product Liability Litigation, MDL No. 2299) , “We ...

(Date:5/25/2013)... TX (PRWEB) May 25, 2013 Studies ... those who are carrying excessive weight and their inability ... for many, simply losing weight can naturally relieve many ... found that improvement in sleep quality was significantly associated ... six month study dated November 6th, 2012, ...

(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...

Breaking Medicine News(10 mins):Health News:idcloak Launches Proxy Web Browser for Blocked Facebook Users 2 Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2 Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2 Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3 Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2 Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2

[0] idcloak Launches Proxy Web Browser for Blocked Facebook Users [0] Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ [0] Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation [0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep [0] Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org

... hearing loss in laboratory animals, according to two new ... of a pill that could stave off noise-induced and ... findings will be reported Wednesday at the Association for ... author Colleen Le Prell, Ph.D., a researcher at the ...

... National Head Start Association (NHSA) issued the following statement ... is the director of the Albina Head Start program ... be created -- and more than 200,000 existing jobs ... has signed into law the economic recovery package containing ...

... Quarterly EPS of $0.39, Total Revenues of $109.1 Million ... Total Revenues by 17% -- Company Generates $178.3 Million ... Gen-Probe Incorporated (Nasdaq: GPRO ... quarter and full year ended December 31, 2008, including ...

... MADISON, Wis., Feb. 17 /PRNewswire-FirstCall/ -- Cogdell ... appointment of Roger Herritz as President of the Midwest ... Inpatient Project Delivery for the Company,s wholly owned subsidiary, ... the Company,s Madison office, Mr. Herritz will be responsible ...

... Lingering physical effects of cancer a likely cause, finds study, ... fighting cancer wasn,t hard enough, a new Dutch study concludes ... be able to find a job. , The meta-analysis of ... those who,d battled cancer were out of work vs. 15.2 ...

... sent today to,President Obama and members of the ... leadership of Congress on the enactment of,the American ... the first time,provides financial incentives to physicians who ... improve both the quality and cost-,effectiveness of patient ...

Vitamin supplements may protect against noise-induced hearing loss NHSA: President Obama, Congress Deserve High Praise for $2.1 Billion in Recovery Package for Head Start Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman One in Three Cancer Survivors on Unemployment Line Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records

The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....

... an electrical power supply, MERKUR offers a broad ... a gas spring for ease of operation. For ... a foot pedal hydraulic system. Thanks to its ... anytime in a highly mobile and flexible manner. ...

... table MARS Enduro is the ideal ... are required before, during or directly ... motorised longitudinal adjustment and the filigreed ... conditions in examination, induction and operating ...

... Top Rotation provides uncommon bi-directional flexibility, ... Hercules 6700B eliminates any conflicts between ... while providing ample leg room for ... procedures. Removable back and leg sections ...

Medicine Products:

VA-500 Merkur Mars Enduro Hercules 6700B